Spot No. |
Name of the Protein/Polypeptide |
Accession Id. |
Mr |
pI |
Mascot Score |
Sequence Coverage |
No. of MS/MS matches |
1. |
Serum Albumin-Human |
1BKE |
65,993 |
5.69 |
191(64) |
64% |
9 |
2. |
Alpha-1-B-Glycoprotein-Human |
Q68CK0_HUMAN |
54,220 |
5.56 |
160(64) |
48% |
7 |
3. |
Alpha-1-antitrypsin-Human |
AAB59495 |
46,677 |
5.43 |
110(64) |
36% |
8 |
4. |
Vitronectin precursor-Human |
SGHU1V |
54,328 |
5.55 |
112(64) |
23% |
5 |
5. |
Kininogen, HMW precursor |
KGHUH1 |
71,900 |
6.34 |
115(64) |
40% |
6 |
6. |
Prothrombin-Human |
Q4QZ40_HUMAN |
69,920 |
5.70 |
202(64) |
48% |
8 |
7. |
Plasma protease C1 inhibitor (fragment)-Human |
Q59EI5_HUMAN |
56,695 |
5.98 |
116(64) |
27% |
7 |
8. |
Complement C1 inhibitor precursor-Human |
ITHUC1 |
55,119 |
6.09 |
105(64) |
29% |
5 |
9. |
Vitamin D binding protein-Human |
Q53F31_HUMAN |
52,916 |
5.34 |
221(64) |
51% |
8 |
10. |
Alpha-2-HS-glycoprotein precursor-Human |
WOHU |
39,300 |
5.43 |
158(64) |
40% |
5 |
11. |
Haptoglobin precursor-Human |
HPHU1 |
38,427 |
6.13 |
242(64) |
29% |
5 |
12. |
Human apolipoprotein-A-IV |
AAA51748 |
43,358 |
5.22 |
494(64) |
61% |
9 |
13. |
Complement component C3d-Human |
1C3D |
32,845 |
6.34 |
219(64) |
44% |
6 |
*14. |
Haptoglobin precursor |
HPHU1 |
38,427 |
6.13 |
75(64) |
14% |
1 |
*15. |
Complement component C3b-Human |
S27041 |
25,280 |
4.49 |
49(64) |
55% |
4 |
16. |
a1-microglobulin |
HCHU |
38,974 |
5.95 |
95(64) |
35% |
5 |
17. |
APOA1 protein (fragment)-Human |
CAA00975 |
28,061 |
5.27 |
470(64) |
81% |
11 |
18. |
Serum amyloid P-Human |
YLHUP |
25,371 |
6.10 |
181(64) |
30% |
4 |
19. |
Preproapolipoprotein A1-Human |
LPHUA1 |
30,759 |
5.56 |
173(64) |
59% |
7 |
20. |
Transthyretin chain A-Human |
2TRYA |
13,829 |
5.35 |
216(64) |
94% |
5 |
21. |
Human a fetoprotein |
E973181 |
66,358 |
5.67 |
264(64) |
49% |
6 |
22. |
Transferrin-Human |
Q53H26_HUMAN |
77,030 |
6.68 |
339(64) |
51% |
8 |
23. |
Fibrinogen b chain-Human |
FGHUB |
55,892 |
8.54 |
592(64) |
49% |
10 |
24. |
Fibrinogen α chain-Human |
FGHUA |
69,714 |
8.23 |
508(64) |
38% |
8 |
25. |
Fibrinogen b chain fragment d-Human |
1FZAB |
35,875 |
7.66 |
253(64) |
79% |
5 |
26. |
Voltage gated Ca channel a2d3 subunit-Human |
Q8IZS8_HUMAN |
122,933 |
5.53 |
65(64) |
29% |
0 |
27. |
Fibrinogen α chain extended splice form-Human |
D44234 |
94,914 |
5.70 |
204(64) |
35% |
4 |
28. |
Immunoglobulin k light chain VLJ region-Human |
BAC01677 |
27,574 |
7.53 |
160(64) |
33% |
3 |
*29. |
Immunoglobulin k chain V-III region (B6)–Human |
K3HUB6 |
11,628 |
9.34 |
59(64) |
16% |
1 |
30. |
Haptoglobin precursor |
HPHU2 |
45,177 |
6.13 |
71(64) |
53% |
5 |
31. |
Immunoglobulin k chain NIG26 precursor-Human |
JEO242 |
23,504 |
5.46 |
203(64) |
48% |
3 |
*32. |
Immunoglobulin l light chain variable region (fragment)-Human |
AAD16673 |
11,505 |
5.67 |
32(64) |
25% |
1 |
33. |
Hemoglobin a chain (fragment)-Human |
Q9BX3_HUMAN |
10,703 |
7.07 |
87(64) |
60% |
3 |
34. |
Hemoglobin b chain-Human |
2HBSB |
15,827 |
7.26 |
143(64) |
82% |
6 |
35. |
Ig κ light chain VLJ region (fragment)-Human |
BAC01701 |
29,183 |
8.84 |
127(64) |
39% |
4 |
36. |
Anti RhD monoclonal T125 k light chain precursor-Human |
Q5EFE6_HUMAN |
25,682 |
8.70 |
56(64) |
41% |
2 |
37. |
Fibrinogen fragment d, chain C-Human |
1FZEC |
34,457 |
5.68 |
64(64) |
56% |
2 |
38. |
Fibrinogen fragment d, chain B-Human |
1FZAB |
35,875 |
7.66 |
137(64) |
53% |
5 |
39. |
Fibrinogen fragment d, chain F-Human |
1FZEF |
34,343 |
5.68 |
109(64) |
54% |
4 |
40. |
Fibrinogen fragment d, chain C-Human |
1FZAC |
35,144 |
5.57 |
91(64) |
66% |
3 |
41. |
Fibrinogen beta chain precursor |
FIBB_HUMAN |
55,892 |
8.54 |
107(53) |
48% |
5 |
42. |
Fibrinogen γ A chain precursor-Human |
FGHUG |
49,465 |
5.70 |
313(64) |
55% |
9 |
43. |
ALB protein (Growth inhibiting protein 20)-Human |
Q86YGO_HUMAN |
47,330 |
5.97 |
170(64) |
39% |
8 |
44. |
Apolipoprotein-A-IV precursor-Human |
LPHUA4 |
45,307 |
5.23 |
107(64) |
58% |
5 |
45. |
α1-antitrypsin precursor-Human |
ITHU |
46,707 |
5.37 |
248(64) |
55% |
8 |
46. |
Fibrinogen γ B chain precursor-Human |
FGHUGB |
51,479 |
5.37 |
343(64) |
64% |
8 |
47. |
Coagulation factor XIII chain b precursor-Human |
KFHU13 |
75,442 |
5.97 |
94(64) |
34% |
3 |
48. |
Plasminogen-Human |
Q5TEH4_HUMAN |
90,510 |
7.04 |
90(64) |
40% |
6 |
49. |
Fibronectin1-Human |
Q60FE4_HUMAN |
252,848 |
5.66 |
224(64) |
26% |
13 |
50. |
HUMPIS NID (CDC2-related protein kinase)-Human |
AAA60092 |
35,549 |
9.02 |
65(64) |
52% |
1 |
51. |
Replication licensing factor MCM2-Human |
S42228 |
99,174 |
5.72 |
68(64) |
21% |
0 |
52. |
(P02735) Serum amyloid A protein precursor-Human |
SAA_HUMAN |
13,524 |
6.28 |
157(64) |
52% |
2 |
53. |
(P01574) Interferon beta precursor (IFN-beta) (Fibroblast interferon)-Human |
IFNB_HUMAN |
22,279 |
8.93 |
53(53) |
28% |
0 |
54. |
(P61011) Signal recognition particle 54 kDa protein (SRP54) |
SRP54_HUMAN |
55,668 |
8.87 |
53(53) |
16% |
0 |
55. |
Hypothetical protein DKFZp779N0926-Human |
Q7Z664_HUMAN |
45,064 |
5.76 |
547(64) |
46% |
6 |
**56. |
Collagen alpha 1(XI) chain precursor - human |
CGHU1E |
181,029 |
5.11 |
53(64) |
21% |
2 |
57. |
Nicotinic acetylcholine receptor epsilon chain precursor - human |
S34775 |
54,581 |
5.09 |
43(64) |
16% |
1 |
**58. |
Glutathione S-transferase A2 |
GSTA2_HUMAN |
25,531 |
8.54 |
33(64) |
85% |
1 |
59. |
SET domain, bifurcated 1-Human |
Q5SZD8_HUMAN |
27,685 |
4.85 |
45(64) |
24% |
1 |
**60. |
Adenylate Kinase 1-Human |
Q5T9B7_HUMAN |
23,396 |
8.78 |
29(64) |
29% |
2 |
**61. |
Interleukin-14 precursor –Human |
A48203 |
54,723 |
9.32 |
26(64) |
27% |
1 |
62. |
3' Histone mRNA exonuclease1 |
THEX1_HUMAN |
39,907 |
6.32 |
45(64) |
43% |
1 |
63. |
AB009303 NID membrane-type matrix metalloproteinase 3 |
BAA23742 |
69,451 |
8.72 |
58(64) |
34% |
1 |
64. |
Leucine-rich PPR motif-containing protein-Human |
Q7Z7A6_HUMAN |
157,805 |
5.81 |
53(64) |
17% |
1 |
**65. |
BC015875 NID-Human
(Selenoprotein P) |
AAH15875 |
43,157 |
7.59 |
51(64) |
26% |
1 |
**66. |
1-Phosphatidylinositol-4-phosphate 5-kinase-Human |
A55967 |
46,163 |
7.70 |
24(64) |
9% |
1 |
67. |
HSP63G13 NID (p63 protein)-Human |
AAG45609 |
55,652 |
6.41 |
60(64) |
25% |
1 |
68. |
(Q9UPY3) Endoribonuclease Dicer-Human |
DICER_HUMAN |
217,490 |
5.45 |
47(53) |
11% |
1 |
69. |
(P58340) Myeloid leukemia factor 1 |
MLF1_HUMAN |
30,608 |
9.46 |
37(53) |
34% |
2 |
70. |
Matrix metalloprotease MMP-27 |
Q9H306_HUMAN |
58,986 |
8.83 |
36(64) |
23% |
2 |
*71. |
Apolipoprotein E precursor (ApoE) |
APOE_HUMAN |
36,132 |
5.65 |
284(64) |
50% |
7 |
72. |
T-cell receptor b-chain precursor |
CAA71260 |
15,318 |
6.07 |
46(64) |
43% |
1 |
**73. |
Homeobox protein CHX10 |
CHX10_HUMAN |
39,386 |
7.11 |
33(53) |
17% |
1 |
74. |
Ephrin-A1 precursor |
EFNA1_HUMAN |
23,756 |
6.49 |
41(53) |
36% |
1 |
75. |
Intestinal alkaline phosphatase precursor |
PPBI_HUMAN |
56,776 |
5.53 |
36(53) |
18% |
1 |
76. |
Ficolin 3 precursor |
FCN3_HUMAN |
32,868 |
6.20 |
96(64) |
22% |
4 |
77. |
Complement component C4 fragment |
Q5ST68_HUMAN |
32,378 |
8.50 |
146(64) |
37% |
4 |
78. |
Fibrinogen gamma chain precursor |
FIBG_HUMAN |
51,479 |
5.37 |
226(64) |
30% |
6 |
79. |
Transthyretin precursor / Prealbumin (multimer) |
TTHY_HUMAN |
15,877 |
5.52 |
214(64) |
81% |
3 |
80. |
Adrenocorticotrophic hormone (ACTH) (glycosylation shifts Mr and pI) |
CAA00890 |
4,692 |
8.34 |
112(64) |
78% |
1 |
81. |
Alpha-2-macroglobulin precursor (Alpha-2-M) |
A2MG_HUMAN |
163,175 |
6.00 |
74(53) |
18% |
2 |
82. |
Inter-alpha-trypsin inhibitor heavy chain H4 precursor |
ITIH4_HUMAN |
103,294 |
6.51 |
73(53) |
26% |
3 |
83. |
Complement C3 precursor |
CO3_HUMAN |
187,046 |
6.02 |
80(53) |
25% |
3 |
84. |
Alpha-1-acid glycoprotein 1 precursor (Orosomucoid 1) |
A1AG1_HUMAN |
23,497 |
4.93 |
130(53) |
31% |
3 |
85. |
histidine-rich glycoprotein precursor – human (glycosylation shifts pI) |
KGHUGH |
59,541 |
7.09 |
137(64) |
22% |
4 |
86. |
Sodium/hydrogen exchanger 2 (NHE-2) |
SL9A2_HUMAN |
91,461 |
9.20 |
62(53) |
13% |
2 |
87. |
C4A2 (C4A3) |
Q6U2F0_HUMAN |
58,393 |
5.67 |
77(64) |
35% |
6 |
* - protein identifications supported by the published SWISS-2D-PAGE map of human plasma
** - protein identifications supported by other proteomic studies of blood plasma/serum (Ref. 4, 6, 7) |